Canada markets open in 8 hours 37 minutes

Stereotaxis, Inc. (STXS)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.2000+0.0200 (+0.92%)
At close: 04:00PM EDT
2.1500 -0.05 (-2.27%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.1800
Open2.2100
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range2.1500 - 2.2500
52 Week Range1.4000 - 3.2900
Volume184,854
Avg. Volume319,822
Market Cap186.244M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Stereotaxis to Present at Upcoming Investor Conferences

    ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will represent Stereotaxis at two upcoming investor conferences. H.C. Wainwright 26th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 11th, 2024, at 12:30 pm EST and will be available that same day for o

  • GlobeNewswire

    Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress

    ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society (HRS), is focused on exploring digital technologies that advance the boundaries of innovation in cardi

  • GlobeNewswire

    Stereotaxis Reports 2024 Second Quarter Financial Results

    ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024. “We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company,” said David Fischel, Chairman and CEO. “Key milestones achieved includ